Prognosis

Family caregivers can help shape the outcomes for their loved ones – an ICU nurse explains their vital role

Retrieved on: 
Tuesday, April 9, 2024

Marie landed in the intensive care unit where I am a bedside nurse because she was too agitated and needed more oxygen.

Key Points: 
  • Marie landed in the intensive care unit where I am a bedside nurse because she was too agitated and needed more oxygen.
  • As a seasoned bedside critical care nurse, I see firsthand the benefits that family caregivers bring to patient care in the hospital.
  • I also witness the emotional stress that caregivers experience when their loved one comes to the ICU.

Caregivers often battle anxiety and depression

  • From making medical decisions to advocating for their loved one, family caregivers have many important roles when their loved one is in the hospital.
  • However, caregivers carry heavy emotional burdens while supporting loved ones at the hospital.
  • Up to 70% of first-degree relatives of ICU survivors suffer from anxiety symptoms, more than a third suffer from depression, and many can experience symptoms of post-traumatic stress disorder, or PTSD.

Communication is critical

  • As you provide information about the patient at home, the medical team should be giving you updates about the patient’s condition in the hospital.
  • Knowing what to ask is essential to effective communication at the hospital.
  • Once familiar with your new environment, you may feel more at ease to truly be present for your loved one.
  • Every day, the interdisciplinary medical team sees each patient to discuss updates and treatment plans, and answers questions for the patient and their family.
  • Research has also shown that rounds relieve anxiety and stress among family caregivers due to the consistent daily communication and emotional support that they provide.

Nurses can be helpful

  • After clinical rounds, the interdisciplinary team of doctors and nurses establishes a daily plan of care for your loved one, which will be carried out by your bedside nurse.
  • The nurse will give the ordered medications, perform necessary clinical tasks and assess the patient for their response to the treatment.
  • Nurses are the most accessible resource you have when your loved one is in the hospital.

The importance of routines and familiarity

  • Preventing ICU delirium through reorientation and familiar faces can help prevent this serious complication and can even reduce their hospital stay.
  • Most families that come to the hospital describe the support they received from the medical team in a positive way.


Courtney Graetzer does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.

Retrieved on: 
Monday, March 18, 2024

“MLD is a rapidly progressing, life-limiting and ultimately fatal rare disease that has a devastating impact on afflicted children and their families.

Key Points: 
  • “MLD is a rapidly progressing, life-limiting and ultimately fatal rare disease that has a devastating impact on afflicted children and their families.
  • This achievement is the culmination of decades of research and development in partnership with our academic and clinical collaborators at the San Raffaele-Telethon Institute for Gene Therapy.
  • It was previously given both Rare Pediatric Disease (RPD) and Regenerative Medicine Advanced Therapy (RMAT) designations from FDA.
  • Orchard Therapeutics will provide more details about the launch of Lenmeldy in the U.S. through a separate announcement this week.

KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)

Retrieved on: 
Thursday, March 14, 2024

LONDON and SALT LAKE CITY, March 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (Renalytix) announces that the KidneyIntelX In-Vitro Diagnostic test has been included in the final KDIGO (Kidney Disease Improving Global Outcomes) 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD), published on March 13, 2024.

Key Points: 
  • LONDON and SALT LAKE CITY, March 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (Renalytix) announces that the KidneyIntelX In-Vitro Diagnostic test has been included in the final KDIGO (Kidney Disease Improving Global Outcomes) 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD), published on March 13, 2024.
  • In the release of the new guideline, timed to coincide with World Kidney Day on March 14, the KDIGO committee highlighted the role of risk prediction in guiding care for patients.
  • In this context, KidneyIntelX is recommended for use as an externally validated tool for predicting disease progression in people with CKD stages G1-G3.
  • In the KDIGO announcement of the publication of the 2024 CKD guideline, Adeera Levin MD, one of the Guideline Committee Co-Chairs said, “Recent advancements in GFR evaluation, risk prediction, and the arrival of novel treatments are poised to enhance CKD prognosis and management.

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Retrieved on: 
Tuesday, March 12, 2024

The Company has partnered with GEICAM, the largest academic breast cancer research network in Spain, where 38 hospitals have agreed to participate in FLAMINGO-01.

Key Points: 
  • The Company has partnered with GEICAM, the largest academic breast cancer research network in Spain, where 38 hospitals have agreed to participate in FLAMINGO-01.
  • These sites were recently approved by Spanish authorities, which led to site initiation visits and training of the first sites this past week.
  • Founded in 1995, GEICAM is a not-for-profit organization leading academic breast cancer research in Spain.
  • Breast cancer is the leading cause of death in women between the ages 35-45 in Spain with 6,836 deaths in 2022.

IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

Retrieved on: 
Friday, April 5, 2024

Immune‑mediated pneumonitis occurred in 1.3% (5/388) of patients receiving IMFINZI and IMJUDO, including fatal (0.3%) and Grade 3 (0.2%) adverse reactions.

Key Points: 
  • Immune‑mediated pneumonitis occurred in 1.3% (5/388) of patients receiving IMFINZI and IMJUDO, including fatal (0.3%) and Grade 3 (0.2%) adverse reactions.
  • Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (
  • Immune‑mediated colitis or diarrhea occurred in 6% (23/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (3.6%) adverse reactions.
  • Immune-mediated adrenal insufficiency occurred in 1.5% (6/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (0.3%) adverse reactions.

Biological Dynamics Announces Expanding Adoption of ExoVerita™ Pro Under Early Access Program

Retrieved on: 
Tuesday, April 2, 2024

Biological Dynamics, Inc. , a leader in exosome technology, today announced that Hoag has joined the growing list of customers adopting Biological Dynamics’ ExoVerita Pro instrument, a cost-efficient, automated exosomal enrichment platform.

Key Points: 
  • Biological Dynamics, Inc. , a leader in exosome technology, today announced that Hoag has joined the growing list of customers adopting Biological Dynamics’ ExoVerita Pro instrument, a cost-efficient, automated exosomal enrichment platform.
  • ExoVerita Pro supports exosome-based research efforts, helping to accelerate early disease detection, determine therapeutic response, and more.
  • “Research has shown that exosomes carry important information about human health, but studying them has proven challenging,” said Paul R. Billings, MD, Ph.D., CEO and Chairman of Biological Dynamics.
  • Biological Dynamics will showcase ExoVerita Pro in Booth #4340 at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, Calif., April 5-10.

DNA Methylation Detection Technology Market Research 2024 - Global Forecast to 2033 Featuring Prominent Players - Thermo Fisher Scientific, Illumina, QIAGEN, Zymo Research, and Agilent Technologies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 2, 2024

The global DNA methylation detection technology market is projected to experience substantial growth over the forecast period 2023-2033.

Key Points: 
  • The global DNA methylation detection technology market is projected to experience substantial growth over the forecast period 2023-2033.
  • In the DNA methylation detection technology market, several key players dominate the landscape with their diverse range of products and solutions.
  • Thermo Fisher Scientific, Illumina, Inc. QIAGEN, Zymo Research Corporation, and Agilent Technologies, Inc. are among the prominent market players offering innovative tools and platforms for DNA methylation analysis.
  • The global DNA methylation detection technology market can be considered to be in the mature growth stage of its lifecycle.

Global Balloon Catheter Market Analysis Report 2023-2030: Minimally Invasive Solutions and Age-Associated Cardiovascular Problems Drive Demand - ResearchAndMarkets.com

Retrieved on: 
Friday, March 22, 2024

The "Global Balloon Catheter Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Balloon Catheter Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The growing prevalence of age-associated cardiovascular problems propels balloon catheter demand, significantly increasing the medical device market and enhancing the care of growing older populations globally.
  • Offering minimally invasive alternatives to conventional surgeries, balloon catheters lead to faster recuperation instances, decreased dangers, and progressed patient effects, driving market increase towards minimally invasive tactics.
  • By product type, the Global Balloon Catheter Market is divided into Normal Balloon Catheter, Drug Eluting Balloon Catheter, Cutting Balloon Catheter, Scoring Balloon Catheter, Stent Graft Balloon Catheter, and Others.

World Obesity Drugs and Delivery Platforms Research Report 2023: Pipeline Analysis, Drug Delivery Innovations, Outlook, Acquisitions, Partnerships, and Funding - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 21, 2024

The "Growth Opportunities in Obesity Drugs and Delivery Platforms" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Opportunities in Obesity Drugs and Delivery Platforms" report has been added to ResearchAndMarkets.com's offering.
  • In this study, the emerging and recently approved obesity treatment pipelines and associated advances in drug delivery technologies are analyzed.
  • The study also provides insights into funding, the collaborative landscape of obesity treatments and delivery platforms, the clinical trial landscape for obesity management, and the mechanism of action of promising anti-obesity drug candidates.
  • GLP-1-based obesity treatments are fast emerging as potent treatment options for obesity and have a favorable safety profile.